Klin Padiatr 2018; 230(03): 175
DOI: 10.1055/s-0038-1645024
DOI: 10.1055/s-0038-1645024
Top 7 Novel approaches and applications
Monitoring of minimal residual disease in MYCN-amplified neuroblastoma by chromosomal breakpoint recognition
Authors
-
A Szymansky
1 Charité Berlin -
R Menon
2 NEO New Oncology GmbH, Cologne -
MJ Witthauer
1 Charité Berlin -
A Winkler
1 Charité Berlin -
MJ Pogodzinski
1 Charité Berlin -
MD Overath
1 Charité Berlin -
J Toedling
1 Charité Berlin3 DKTK, Berlin -
F Hertwig
1 Charité Berlin3 DKTK, Berlin -
K Schönbeck
1 Charité Berlin -
L Heukamp
6 Institut für Hämatopathologie, Hamburg -
J Heukmann
2 NEO New Oncology GmbH, Cologne -
P Hundsdoerfer
1 Charité Berlin3 DKTK, Berlin4 BIH, Berlin -
A Eggert
1 Charité Berlin3 DKTK, Berlin4 BIH, Berlin -
M Fischer
7 University Hospital Cologne, Germany -
C Eckert
1 Charité Berlin -
JH Schulte
1 Charité Berlin3 DKTK, Berlin4 BIH, Berlin5 DKFZ, Heidelberg
